The service provider selection process is a complicated one. Many factors come into play during this process. One critical factor is undoubtedly the presence of preferred provider agreements. Companies can spend a great deal of time negotiating these agreements and their presence, or lack thereof, can make or break which CROs are shortlisted or awarded a Phase II/III study. ISR asked respondents to share their selection criteria in a manner that reflects the role preferred provider agreements can play in the decision-making process.
Learn more from our Phase II/III CRO Benchmarking (13th Ed.) report.
Originally published in Life Science Leader.
View Resource